SCHEMBL2054715

SCHEMBL2054715

Cn1cnnc1SCC1CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.56
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.49
HSD11B1 P28845 1/20 0.47
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 8/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ELANE P08246 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24866724 0.72 LMNA (0.53) CRBNKMT2APOLBHSD11B1ALDH1A1
SCHEMBL11953074 0.69 ALDH1A1 (0.50) KMT2APOLBHSD11B1ALDH1A1MAPT
SCHEMBL13528425 0.69 ALDH1A1 (0.60) POLBALDH1A1MAPTLMNAELANE
SCHEMBL5717624 0.67 L3MBTL1 (0.57) KMT2APOLBHSD11B1MAPK1ALDH1A1
SCHEMBL22945007 0.67 ALDH1A1 (0.59) KMT2APOLBTSHRMAPK1ALDH1A1
SCHEMBL11512125 0.67 ALDH1A1 (0.48) KMT2APOLBHSD11B1ALDH1A1MAPT
SCHEMBL1770088 0.64 HSD11B1 (1.00) CRBNKMT2APOLBHSD11B1ALDH1A1
SCHEMBL10403664 0.62 KMT2A (0.53) KMT2APOLBHSD11B1ALDH1A1MAPT
SCHEMBL8363511 0.62 POLB (0.60) CRBNPOLBTSHRALDH1A1MAPT
SCHEMBL2054703 0.62 ALDH1A1 (0.41) KMT2APOLBTSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
EP-1899294-A1 THERAPEUTIC AGENTS Merck Sharp & Dohme Limited (GB) 2008-03-19 EP disclosed
WO-2006134341-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286765-A1 Therapeutic Agents GRIA1, GRIN1, GLRA1 CRBN 3677/4885KMT2A 1209/4885POLB 4418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.